Rebalancing movement: A.F. GENESE focuses on non-invasive neuromodulation to alleviate Parkinson's disease and dystonias

Meet Aurélien Fromm, founder and CEO by A.F. GENESE, a startup that is exploring a path that is still unknown but promising: low-frequency electromagnetic neuromodulation to rebalance muscle tone.

Developed in collaboration with Inserm, its portable and non-invasive technology already shows immediate effects on muscular activity.

Objective: to provide a simple, accessible and scientifically validated answer to dystonias and motor disorders present in Parkinson's disease and other neurodegenerative pathologies.

‍

Can you introduce yourself and explain to us what A.F. Genese does?

Aurélien Fromm:

“Hello, I am Aurélien Fromm, president and founder of A.F. GENESE. We are developing a low frequency electromagnetic stimulation solution.
This solution, developed over the last five years in collaboration with Inserm (collaboration that resulted in a joint patent) is now portable, autonomous and, above all, non-invasive. It complies with electromagnetic exposure standards and has an instantaneous and systemic effect, observed through various clinical tests. First, thanks to a dynamometer, we were able to demonstrate an increase in muscular resistance. Second, using surface electromyograms, we observed a change in muscular electrical activity at a distance from stimulation.”

‍

How does your device actually work?

Aurélien Fromm:

“Today, the solution is applied continuously to the arm. Its aim is to regulate muscle tone throughout the body and to compensate for dystonia problems that may lead to postural disorders, associated pain or movement disorders.”

‍

What is the mission of A.F. Genesis?

Aurélien Fromm:

“Our mission is to develop a solution for regulating muscle tone to alleviate the dystonias observed in neurodegenerative diseases such as Parkinson's disease, and thus meet the needs of thousands of patients.”

‍

What makes you wake up in the morning?

Aurélien Fromm:

“What makes me wake up in the morning is the need and the desire to respond to the health problems that patients face on a daily basis. It is also a passion to use technological innovation and our scientific knowledge to push the current limits of care quality.”

‍

The bonus question: what is your definition of success?

Aurélien Fromm:

“Success is about achieving the goal we have set ourselves: to help patients and enable them to return to normal life. We will consider that we have achieved it when our solution succeeds, and when it is adopted as widely as possible.”

‍